Regulation of cancer metastasis by stress pathways

Clinical and Experimental Metastasis

Volumn 20, Issue 1, 2003, Pages 31-43

  Xie, Keping ^a   Huang, Suyun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acidosis; Free radicals; Hypoxia; Metastasis; Signal transduction

Indexed keywords

BETA INTERFERON; CYTOKINE; FREE RADICAL; GAMMA INTERFERON; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; S (2,3 DIDODECANOYLOXYPROPYL) N HEXADECANOYLCYSTEINYLALANYL DEXTRO ISOGLUTAMINYLGLYCYLTAURINE;

ACIDOSIS; ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; HUMAN; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TUMOR BLOOD FLOW;

ACIDOSIS; ANOXIA; FREE RADICALS; HEAT-SHOCK PROTEINS; HUMANS; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION;

EID: 0037217892     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022590402748     Document Type: Review

References (219)

1. Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987; 24: 137-209.
2. Weiss L. Principles of Metastasis. Academic Press, Orlando, 1985.
3. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58-65.
4. Fidler IJ. biologic heterogeneity of cancer metastases. Breast Cancer Res Treat 1987; 9: 17-26.
5. Sugarbaker EV. Cancer metastasis: A product of tumor - host interactions. Curr Probl Cancer 1979; 3: 1-59.
6. Weiss L. Biomechanical interactions of cancer cells with the microvasculature during hematogenous metastasis. Cancer Metastasis Rev 1992; 11: 227-35.
7. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130-38.
8. Price JE, Aukerman SL, Fidler IJ. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 1986; 46: 5172-8.
9. Aukerman SL, Price JE, Fidler IJ. Different deficiencies in the prevention of tumorigenic-low metastatic murine K-1735 melanoma cells from producing metastases. J Natl Cancer Inst 1986; 77: 915-24.
10. Weiss L. Metastasis of cancer: A conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 2000, 19: I-XI, 193-383.
11. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73.
12. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054s-59s.
13. Nabi IR, Watanabe H, Raz A. Autocrine motility factor and its receptor: Role in cell locomotion and metastasis. Cancer Metastasis Rev 1992; 11(1): 5-20.
14. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449-65.
15. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 1990; 50: 4478-84.
16. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997-1004.
17. Xie K, Wang B, Shi Q et al. Mouse models of metastatic pancreatic adenocarcinoma. Intl J Pancreatol 2001; 29: 21-7.
18. Shi Q, Xie K. Experimental animal models for pancreatic cancer. Int J Oncol 2000; 17: 217-25.
19. 125I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970; 45: 773-82.
20. Glaves D. Intravascular death of disseminated cancer cells mediated by superoxide anion. Invasion Metastasis 1986; 6: 101-11.
21. Paris S, Chauzy C, Martin-Vandelet N et al. A model of spontaneous lung metastases visualised in fresh host tissue by green fluorescent protein expression. Clin Exp Metastasis 1999; 17: 817-22.
22. Chishima T, Miyagi Y, Wang X et al. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 1997; 57: 2042-7.
23. Naumov GN, Wilson S, MacDonald IC et al. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci 1999; 112: 1835-42.
24. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893-5.
25. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990; 322: 605-12.
26. Talmadge JE, Fidler IJ. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst 1982; 69: 975-80.
27. Liotta LA, Kleinerman J, Saidel GM. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36: 889-94.
28. Chambers AF, Schmidt EE, MacDonald IC et al. Early steps in hematogenous metastasis of B16F1 melanoma cells in chick embryos studied by high-resolution intravital videomicroscopy. J Natl Cancer Inst 1992; 84: 797-803.
29. Luzzi KJ, MacDonald IC, Schmidt EE et al. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Patrol 1998; 153: 865-73.
30. Xie K, Fidler IJ. TNF-mediated cytotoxicity in sensitive and resistant L929 fibroblasts correlates with nitric oxide-independent and -dependent mechanisms, respectively. J Leuk Biol (Suppl) 1992; 3: 45.
31. Xie K, Huang S, Dong Z et al. Cytokine-induced apoptosis in transformed murine fibroblasts involves synthesis of endogenous nitric oxide. Int J Oncol 1993; 3: 1043-7.
32. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76(5): 589-605.
33. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001; 3(5): 323-7.
34. Dachs GU, Tozer GM. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000; 36 (13 Spec No): 1649-60.
35. Xie K, Fidler IJ. Gene therapy with the inducible nitric oxide synthase for induction of apoptosis to control tumor growth and metastasis. Cancer Metastasis Rev 1998; 17: 255-75.
36. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J 1996; 313 (Pt 1): 17-29.
37. Wouters BG, Weppler SA, Koritzinsky M et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38(2): 240-57.
38. Kallinowski F, Vaupel P, Runkel S et al. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 1988; (24 Pt 1): 7264-72.
39. Intaglietta M, Johnson PC, Winslow RM. Microvascular and tissue oxygen distribution. Cardiovasc Res 1996; 32(4): 632-43.
40. Shubik P. Vascularization of tumors: A review. J Cancer Res Clin Oncol 1982; 103(3): 211-26.
41. Jain RK. Determinants of tumor blood flow: A review. Cancer Res 1988; 48(10): 2641-58.
42. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 1987; 47(2): 597-601.
43. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984; 2(4): 343-66.
44. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49(16): 4373-84.
45. Sostman HD, Rockwell S, Sylvia AL et al. Evaluation of BA1112 rhabdomyosarcoma oxygenation with microelectrodes, optical spectrophotometry, radiosensitivity, and magnetic resonance spectroscopy. Magn Reson Med 1991; 20(2): 253-67.
46. Höckel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
47. Halliwell B. The antioxidant paradox. Lancet 2000; 355(9210): 1179-80.
48. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996; 32A(1): 30-8.
49. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997; 11(6): 443-8.
50. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-64.
51. Moncada S. Nitric oxide: Discovery and impact on clinical medicine. J R Soc Med 1999; 92: 164-9.
52. Wink DA, Vodovotz Y, Laval J et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19: 711-21.
53. Melillo G, Musso T, Sica A et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Expl Med 1995; 182: 1683-93.
54. Bellocq A, Suberville S, Philippe C et al. Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-kappaB activation. J Biol Chem 1998; 273: 5086-92.
55. Shi Q, Xiong Q, Wang B et al. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res 2000; 60: 2579-83.
56. Wang B, Xiong Q, Shi Q et al. Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res 2001; 61: 71-5.
57. Wang B, Xiong Q, Shi Q et al. Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene 2001; 20: 6930-7.
58. Wang B, Xiong Q, Shi Q et al. Genetic disruption of host nitric oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusion. Int J Cancer 2001; 91: 607-11.
59. Xie K, Wang Y, Huang S et al. Nitric oxide-mediated apoptosis of K-1735 murine melanma cells is associated with down-regulation of Bcl-2. Oncogene 1997; 15: 771-9.
60. Shi Q, Huang S, Jiang W et al. Direct correlation between nitric oxide synthase II inducibility and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant p53. Cancer Res 1999; 59: 2072-5.
61. Höckel M, Schlenger K, Arai B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
62. Brizel DM, Scully SP, Harrelson JM et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3.
63. Rofstad EK, Sundfør K, Lyng H, Tropé CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83: 354-9.
64. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 1988; 85: 9533-7.
65. Jang A, Hill RP. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis 1997; 15: 469-83.
66. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999; 80: 1697-07.
67. De Jaeger K, Kavanagh M-C, Hill RP. Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer 2001; 84: 1280-5.
68. De Jaeger K, Merlo FM, Kavanagh M-C et al. Heterogeneity of tumor oxygenation: Relationship to tumor necrosis, tumor size, and metastasis. Int J Radiat Oncol Biol Phys 1998; 42: 717-1.
69. Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93(4): 266-76.
70. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56(24): 5754-7.
71. Sharma RC, Schimke RT. The propensity for gene amplification: A comparison of protocols, cell lines, and selection agents. Mutat Res 1994; 304(2): 243-60.
72. Russo CA, Weber TK, Volpe CM et al. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res 1995; 55(5): 1122-8.
73. Janssen YM, Van Houten B, Borm PJ et al. Cell and tissue responses to oxidative damage. Lab Invest 1993; 69(3): 261-74.
74. Windle BE, Wahl GM. Molecular dissection of mammalian gene amplification: New mechanistic insights revealed by analyses of very early events. Mutat Res 1992; 276(3): 199-224.
75. Schimke RT, Roos DS, Brown PC. Amplification of genes in somatic mammalian cells. Methods Enzymol 1987; 151: 85-104.
76. Windle B, Draper BW, Yin YX et al. A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 1991; 5(2): 160-74.
77. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997; 11 (6): 443-8.
78. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
79. Gammack H, Byrne M, Lewis CE. Estimating the selective advantage of mutant p53 tumour cells to repeated rounds of hypoxia. Bull Math Biol 2001; 63: 135-66.
80. Kim DCY, Tsai MH, Osmanian C et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997; 57: 4200-4.
81. Royds JA, Dower SK, Qwarnstrom EE et al. Response of tumour cells to hypoxia: Role of p53 and NF-κB. Mol Pathol 1998; 51: 55-61.
82. Zundel W, Schindler C, Haas-Kogan D et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391-45.
83. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: Implications for clonal selection during colorectal carcinogenesis. Oncogene 1999; 18(21): 3199-204.
84. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
85. Wang GL, Jiang BH, Rue EA et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4.
86. Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 1990; 86: 670-4.
87. McQuillan LP, Leung GK, Marsden PA et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994; 267: H1921-7.
88. Goldberg MA, Glass GA, Cunningham JM et al. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987; 84: 7972-6.
89. Firth JD, Ebert BL, Pugh CW et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-500.
90. Semenza GL, Roth PH, Fang HM et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269: 23757-63.
91. Sivitz WI, Lund DD, Yorek B et al. Grover-McKay M, Schmid PG. Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. Am J Physiol 1992; 263: E562-9.
92. Ebert BL, Gleadle JM, O'Rourke JF et al. Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: Similarities with the regulation of erythropoietin. Biochem J 1996; 313: 809-14.
93. Ausserer WA, Bourrat-Floeck B, Green CJ et al. Regulation of c-jun expression during hypoxic and low-glucose stress. Mol Cell Biol 1994; 14: 5032-42.
94. Santilli SM, Fiegel VD, Aldridge DE et al. Rabbit aortic endothelial cell hypoxia induces secretion of transforming growth factor beta and augments macrophage adhesion in vitro. Ann Vasc Surg 1991; 5: 429-38.
95. Gleadle JM, Ebert BL, Firth JD et al. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 1995; 268: C1362-8.
96. Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 1998; 91: 3300-7.
97. Mishra RR, Adhikary G, Simonson MS et al. Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression. Brain Res Mol Brain Res 1998; 59(1): 74-83.
98. Krtolica A, Krucher NA, Ludlow JW. Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities. Oncogene 1998; 17: 2295-304.
99. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-90.
100. Graham CH, Forsdike J, Fitzgerald CJ et al. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999; 80(4): 617-23.
101. Laderoute KR, Grant TD, Murphy BJ et al. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 1992; 52(3): 428-32.
102. Himelstein BP, Koch CJ. Studies of type IV collagenase regulation by hypoxia. Cancer Lett 1998, 124(2): 127-33.
103. Shi Q, Abbruzzese JL, Huang S et al. Constitutive and inducible interleukin-8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res 1999; 5: 3711-21.
104. Shi Q, Le X, Abbruzzese JL et al. Cooperation between transcription factor AP-4 and NF-κB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res 1999; 19: 1363-1.
105. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12: 375-91.
106. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-4.
107. Graeber TG, Peterson JF, Tsai M et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-77.
108. Yah SF, Zou YS, Mendelsohn M et al. Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. J Biol Chem 1997; 272: 4287-94.
109. Yao KS, Xanthoudakis S, Curran T et al. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol 1994; 14: 5997-6003.
110. Yan SF, Lu J, Zou YS et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999; 274: 15030-40.
111. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 1994; 54: 1425-30.
112. Semenza L. Hypoxia-inducible factor 1: Control of oxygen homeostasis in health and disease. Pediatr Res 2001; 49: 614-7.
113. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-54.
114. Madan A, Curtin PT. A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc Natl Acad Sci USA 1993; 90: 3928-32.
115. Minchenko A, Salceda S, Bauer T et al. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994; 40: 35-9.
116. Melillo G, Musso T, Sica A et al.A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 182: 1683-93.
117. Gerber HP, Condorelli F, Park J et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272: 23659-67.
118. Iyer NV, Kotch LE, Agani F et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-62.
119. Kim KW, Bae SK, Lee OH et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58(2): 348-51.
120. Beck I, Weinmann R, Caro J. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 1993; 82: 704-11.
121. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 268: 21513-8.
122. Ebert BL, Bunn HF. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol 1998; 18: 4089-96.
123. Salceda S, Caro J. Hypoxia-inducible factor lalpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642-7.
124. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35(2): 71-103.
125. Jang A, Hill RP. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis 1997; 15(5): 469-83.
126. Sciandra JJ, Subjeck JR. The effects of glucose on protein synthesis and thermosensitivity in Chinese hamster ovary cells. J Biol Chem 1983; 258(20): 12091-3.
127. Pouyssegur J, Shiu RP, Pastan I. Induction of two transformation-sensitive membrane polypeptides in normal fibroblasts by a block in glycoprotein synthesis or glucose deprivation. Cell 1977; 11(4): 941-7.
128. Mosser DD, Kotzbauer PT, Sarge KD et al. In vitro activation of heat shock transcription factor DNA-binding by calcium and biochemical conditions that affect protein conformation. Proc Natl Acad Sci USA 1990; 87(10): 3748-52.
129. Whelan SA, Hightower LE. Differential induction of glucose-regulated and heat shock proteins: Effects of pH and sulfhydryl-reducing agents on chicken embryo cells. J Cell Physiol 1985; 125(2): 251-8.
130. Scott PA, Gleadle JM, Bicknell R et al. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer 1998; 75(5): 706-12.
131. Shweiki D, Neeman M, Itin A et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92(3): 768-72.
132. Martinez-Zaguilan R, Seftor EA, Seftor RE et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14(2): 176-86.
133. Kato Y, Nakayama Y, Umeda M et al. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 1992; 267(16): 11424-30.
134. Sloane BF, Rozhin J, Krepela E et al. The malignant phenotype and cysteine proteinases. Biomed Biochim Acta 1991; 50(4-6): 549-54.
135. Gottlieb RA, Giesing HA, Engler RL et al. The acid deoxyribonuclease of neutrophils: A possible participant in apoptosis-associated genome destruction. Blood 1995; 86(6): 2414-8.
136. Morana SJ, Wolf CM, Li J et al. The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. J Biol Chem 1996; 271(30): 18263-71.
137. Collins MK, Furlong IJ, Malde P et al. An apoptotic endonuclease activated either by decreasing pH or by increasing calcium. J Cell Sci 1996; 109 (Pt 9): 2393-9.
138. Schlappack OK, Zimmermann A, Hill RP. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 1991; 64(4): 663-70.
139. Rozhin J, Sameni M, Ziegler G et al. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54(24): 6517-25.
140. Turner GA. Increased release of tumour cells by collagenase at acid pH: A possible mechanism for metastasis. Experientia 1979; 35(12): 1657-8.
141. Morisset M, Capony F, Rochefort H. The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986; 138(1): 102-9.
142. van der Stappen JW, Williams AC, Maciewicz RA et al. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996; 67(4): 547-54.
143. Marx E, Mueller-Klieser W, Vaupel P. Lactate-induced inhibition of tumor cell proliferation. Int J Radiat Oncol Biol Phys 1988; 14(5): 947-55.
144. Bourrat-Floeck B, Groebe K, Mueller-Klieser W. Biological response of multicellular EMT6 spheroids to exogenous lactate. Int J Cancer 1991; 47(5): 792-9.
145. Shi Q, Le X, Wang B et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001; 20: 3751-6.
146. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
147. Kim CY, Tsai MH, Osmanian C et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997: 57(19): 4200-4.
148. Pipili-Synetos E, Papageorgiou A, Sakkoula E et al. Inhibition of angiogenesis, tumor growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116: 1829-4.
149. Yamamoto T, Terada N, Nishizawa Y et al. Effects of NG-nitro-L-arginine and/or L-arginine on experimental pulmonary metastasis in mice. Cancer Lett 1994; 87: 115-20.
150. Yamamoto T, Terada N, Seiyama A et al. Increase in experimental pulmonary metastasis in mice by L-arginine under inhibition of nitric oxide production by NG-nitro-L-arginine methyl ester. Int J Cancer 1998; 75: 140-4.
151. Iwasaki T, Higashiyama M, Kuriyama K et al. NG-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn J Cancer Res 1997; 88: 861-6.
152. Li L, Nicolson GL, Fidler IJ. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 1991; 51: 245-54.
153. Fidler IJ. Macrophages and metastasis - a biological approach to cancer therapy: Presidential address. Cancer Res 1985; 45: 4714-21.
154. Rocha M, Kruger A, Van Rooijen N et al. Liver endothelial cells participate in T-cell-dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo. Intl J Cancer 1995; 63: 405-11.
155. Edmiston KH, Shoji Y, Mizoi T et al. Role of nitric oxide and superoxide anion in elimination of low metastatic human colorectal carcinomas by unstimulated hepatic sinusoidal endothelial cells. Cancer Res 1998; 58: 1524-31.
156. Wang HH, McIntosh AR, Hasinoff BB et al. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: A natural hepatic defense against metastasis. Cancer Res 2000; 60: 5862-9.
157. Hibbs JR, Taintor JB, Vavrin RR. Macrophage cytotoxicity: Role for L-arginine deiminase activity and amino nitrogen to nitrate. Science 1987; 235: 473-6.
158. Dong Z, Qi X, Xie K et al. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccride-responsive and lipopolysaccride-nonresponsive murine macrophages. J Immunol 1993; 151: 2717-4.
159. Dong Z, Yang X, Xie K et al. Activation of inducible nitric oxide synthase in the murine macrophages by interferon-gamma and lipopolysacchride required protein phosphatase I and protein phosphatase 2A activities. J Leuk Biol 1995; 58: 725-32.
160. Umansky V, Schirrmacher V. Nitric oxide-induced apoptosis in tumor cells. Adv Cancer Res 200; 82: 107-31.
161. Farias-Eisner R, Sherman MP, Aeberhard E et al. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994; 91: 9407-11.
162. Xie K, Huang S, Dons Z et al. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 1995; 55: 3123-31.
163. Radomski MK, Jenkins DC, Holmes L et al. Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 1991; 51: 6073-7.
164. Dong Z, Staroselsky AH, Qi X et al. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 1994; 54: 789-93.
165. Wang B, Wei D, Crum VE et al. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. In press, 2003.
166. Xie K, Huang S, Dong Z et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis in K-1735 murine melanoma cells. J Exp Med 1995; 181: 1333-43.
167. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001; 61: 1100-6.
168. Mackenzie-Graham AJ, Mitrovic B, Smoll A et al. Differential sensitivity to nitric oxide in immortalized, cloned murine oligodendrocyte cell lines. Dev Neurosci 1994; 16: 162-71.
169. Espey MG, Miranda KM, Pluta RM et al. Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals. J Biol Chem 2000; 275: 11341-7.
170. Wink DA, Miranda KM, Espey MG. Cytotoxicity related to oxidative and nitrosative stress by nitric oxide. Exp Biol Med (Maywood) 2001; 226: 621-3.
171. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996; 9: 836-44.
172. Petit JF, Nicaise M, Lepoivre M et al. Protection by glutathione against the antiproliferative effects of nitric oxide. Dependence on kinetics of no release. Biochem Pharmacol 1996; 52: 205-12.
173. Schwarz MA, Lazo JS, Yalowich JC et al. Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc Natl Acad Sci USA 1995; 92: 4452-6.
174. Farias-Eisner R, Chaudhuri G, Aeberhard E et al. The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistence/susceptibilty. J Biol Chem 1996; 271: 6144-51.
175. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997; 11: 443-8.
176. Shi Q, Huang S, Jiang W et al. Direct correlation between nitric oxide synthase II inducibility and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant p53. Cancer Res 1999; 59: 2072-5.
177. Xie K, Huang S, Wang Y et al. Bcl-2 protects cytokine-induced nitric oxide-dependent apoptosis. Cancer Immunol Immunother 1996; 43: 109-15.
178. Brockhaus F, Brune B. U937 apoptotic cell death by nitric oxide: Bcl-2 downregulation and caspase activation. Exp Cell Res 1998; 238: 33-41.
179. Messmer UK, Reed UK, Brune B. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J Biol Chem 1996; 271: 20192-7.
180. Sandau K, Pfeilschifter J, Brune B. Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kidney Int 1997; 52: 378-86.
181. 2+ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. Mol Carcinog 1999; 26: 201-11.
182. Ing DJ, Zang J, Dzau VJ et al. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 1999; 84: 21-33.
183. von Knethen A, Brockhaus F, Kleiter I et al. NO-Evoked macrophage apoptosis is attenuated by cAMP-induced gene expression. Mol Med 1999; 5: 672-84.
184. Umansky V, Ushmorov A, Ratter F et al. Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas). Int J Oncol 2000; 16: 109-17.
185. Chlichlia K, Peter ME, Rocha M et al. Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 1998; 91: 4311-20.
186. Kim YM, de Vera ME, Watkins SC et al. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by
187. Nisoli E, Regianini L, Bulbarelli A et al. Protective effects of noradrenaline against tumor necrosis factor-alpha-induced apoptosis in cultured rat brown adipocytes: Role of nitric oxide-induced heat shock protein 70 expression. Int J Obes Relat Metab Disord 2001; 25: 1421-30.
188. Mannick JB, Asano K, Izumi K et al. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein - Barr virus reactivation. Cell 1994; 79: 1137-46.
189. Genaro AM, Hortelano S, Alvarez A et al. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest 1995; 95: 1884-90.
190. Saavedra JE, Billiar TR, Williams DL et al. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor pro-drag that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver. J Med Chem 1997; 40: 1947-54.
191. Tzeng E, Billiar TR, Williams DL et al. Adenovirus-mediated inducible nitric oxide synthase gene transfer inhibits hepatocyte apoptosis. Surgery 1998; 124: 278-83.
192. Orucevic A, Lala PK. Role of nitric oxide in 1L-2 therapy-induced capillary leak syndrome. Cancer Metastasis Rev 1998; 17: 127-42.
193. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumor progression. Lancet Oncol 2001; 2: 149-56.
194. Xie K, Huang S, Dong Z et al. Destruction of bystander cells by tumor cells transfected with the inducible nitric oxide synthase gene. J Natl Cancer Inst 1997; 89: 421-7.
195. Huang S, Xie K, Ullrich SE et al. Transfection of interleukin-10 suppresses tumorigenicity and metastasis of human melanoma by inhibiting angiogenesis. Clin Cancer Res 1996; 2: 1961-79.
196. Kundu N, Dorsey R, Jackso MJ et al. Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 1998; 76: 713-9.
197. Bruns CJ, Shinohara H, Harbison MT et al. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res 2000; 60: 2-7.
198. Calderon C, Huang ZH, Gage DA et al. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidylserine. J Exptl Med 1995; 180: 945-58.
199. Juang S-H, Xie K, Xu L et al. Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retrviral vectors harboring the marine inducible nitric oxide synthase gene. Human Gene Ther 1998; 9: 845-54.
200. Rojas A, Joiner MC, Denekamp J. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy. Radiother Oncol 1992; 24: 1234.
201. Fenton BM, Lord EM, Paoni SF. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation. Radiat Res 2000; 153: 75-83.
202. Hoskin PJ, Saunders MI, Dische S. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 1999; 86: 1322-8.
203. Miralbell R, Mornex F, Greiner R et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999; 17: 3143-9.
204. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10-21.
205. Saunders M, Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer Suppl 1996; 27: S271-8.
206. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000; 48: 791-5.
207. Kovacs MS, Hocking DJ, Evans JW et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 1999; 80: 1245-51.
208. Patterson LH, McKeown SR. AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000; 83: 1589-93.
209. Yazawa K, Fujimori M, Amano J et al. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000; 7: 269-74.
210. Nuyts S, Van Mellaert L, Theys J et al. The use of radiation-induced bacterial promoters in anaerobic conditions: A means to control gene expression in clostridium-mediated therapy for cancer. Radiat Res 2001; 155: 716-23.
211. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
212. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990; 9: 267-82.
213. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
214. Asano M, Yukita A, Matsumoto T et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 185-90.
215. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
216. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000; 7: 493-8.
217. Kung AL, Wang S, Klco JM et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-40.
218. Dachs GU, Tozer GM. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000; 36: 1649-60.
219. Russo SM, Tepper JE, Baldwin AS, Jr et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183-193.